Aspiriant LLC’s iShares Russell 2000 Value ETF IWN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$15.1M Sell
79,883
-2,532
-3% -$490K 0.43% 35
2025
Q4
$14.9M Sell
82,415
-2,257
-3% -$405K 0.43% 34
2025
Q3
$15M Sell
84,672
-289
-0.3% -$48.8K 0.46% 35
2025
Q2
$13.4M Sell
84,961
-901
-1% -$134K 0.43% 34
2025
Q1
$13M Buy
85,862
+16
+0% +$2.58K 0.45% 31
2024
Q4
$14.1M Buy
85,846
+1,564
+2% +$267K 0.51% 29
2024
Q3
$14.1M Sell
84,282
-4,908
-6% -$797K 0.53% 28
2024
Q2
$13.6M Sell
89,190
-2,212
-2% -$338K 0.55% 30
2024
Q1
$14.5M Sell
91,402
-3,040
-3% -$460K 0.6% 27
2023
Q4
$14.7M Sell
94,442
-1,001
-1% -$139K 0.66% 26
2023
Q3
$12.9M Sell
95,443
-1,956
-2% -$280K 0.66% 25
2023
Q2
$13.7M Buy
97,399
+1,184
+1% +$160K 0.69% 25
2023
Q1
$13.2M Sell
96,215
-1,297
-1% -$188K 0.69% 25
2022
Q4
$13.5M Sell
97,512
-3,579
-4% -$505K 0.69% 23
2022
Q3
$13M Sell
101,091
-5,319
-5% -$769K 0.64% 26
2022
Q2
$14.5M Sell
106,410
-2,261
-2% -$336K 0.7% 24
2022
Q1
$17.5M Sell
108,671
-349
-0.3% -$55.6K 0.96% 18
2021
Q4
$18.1M Sell
109,020
-2,282
-2% -$380K 0.97% 19
2021
Q3
$17.8M Sell
111,302
-20,102
-15% -$3.23M 1.05% 18
2021
Q2
$21.8M Buy
131,404
+24,521
+23% +$4.04M 1.23% 15
2021
Q1
$17M Sell
106,883
-1,814
-2% -$274K 1.09% 18
2020
Q4
$14.3M Buy
108,697
+4,687
+5% +$553K 0.98% 18
2020
Q3
$10.3M Sell
104,010
-3,869
-4% -$393K 0.81% 21
2020
Q2
$10.5M Buy
107,879
+85,552
+383% +$7.78M 0.98% 19
2020
Q1
$1.83M Buy
22,327
+12,874
+136% +$1.44M 0.18% 52
2019
Q4
$1.22M Buy
9,453
+1,961
+26% +$242K 0.11% 79
2019
Q3
$895K Sell
7,492
-1,682
-18% -$199K 0.08% 115
2019
Q2
$1.1M Sell
9,174
-617
-6% -$74.5K 0.09% 100
2019
Q1
$1.17M Sell
9,791
-6,411
-40% -$766K 0.1% 100
2018
Q4
$1.74M Buy
16,202
+4,519
+39% +$544K 0.13% 83
2018
Q3
$1.55M Buy
11,683
+6
+0.1% +$808 0.13% 91
2018
Q2
$1.54M Sell
11,677
-524
-4% -$67.5K 0.13% 90
2018
Q1
$1.49M Buy
12,201
+9,823
+413% +$1.23M 0.13% 83
2017
Q4
$299K Sell
2,378
-11,710
-83% -$1.46M 0.09% 63
2017
Q3
$1.75M Sell
14,088
-4,660
-25% -$549K 0.15% 83
2017
Q2
$2.23M Sell
18,748
-1,116
-6% -$131K 0.19% 73
2017
Q1
$2.35M Sell
19,864
-2,542
-11% -$302K 0.2% 77
2016
Q4
$2.67M Sell
22,406
-585
-3% -$64.7K 0.24% 60
2016
Q3
$2.41M Sell
22,991
-3,157
-12% -$324K 0.24% 61
2016
Q2
$2.54M Sell
26,148
-1,958
-7% -$186K 0.24% 68
2016
Q1
$2.62M Sell
28,106
-2,245
-7% -$195K 0.25% 59
2015
Q4
$2.79M Buy
30,351
+21,994
+263% +$2.09M 0.31% 28
2015
Q3
$753K Sell
8,357
-340
-4% -$32.6K 0.06% 57
2015
Q2
$887K Sell
8,697
-946
-10% -$97.4K 0.09% 54
2015
Q1
$995K Sell
9,643
-848
-8% -$85.6K 0.13% 39
2014
Q4
$1.07M Sell
10,491
-6,517
-38% -$639K 0.14% 37
2014
Q3
$1.59M Sell
17,008
-8,288
-33% -$820K 0.22% 25
2014
Q2
$2.61M Sell
25,296
-222
-0.9% -$22.1K 0.36% 20
2014
Q1
$2.57M Buy
25,518
+109
+0.4% +$10.7K 0.37% 21
2013
Q4
$2.53M Buy
25,409
+5,851
+30% +$559K 0.39% 21
2013
Q3
$1.79M Sell
19,558
-2,207
-10% -$199K 0.32% 16
2013
Q2
$1.87M Buy
+21,765
New +$1.84M 0.29% 22

Other funds holding IWN

Aspiriant LLC's IWN Position: Q1 2026 in Review

Aspiriant LLC reduced its iShares Russell 2000 Value ETF (IWN) stake by 3.1% in Q1 2026, selling an estimated $490K and leaving 79,883 shares worth $15.1M. The position accounts for 0.43% of the portfolio, ranked #35.

Aspiriant LLC first reported a position in IWN in Q2 2013 and has held it in 52 quarters since. The position peaked at $21.8M in Q2 2021. 1,028 funds tracked by Wall St. Rank hold IWN as of Q1 2026.

  • Aspiriant LLC held 79,883 shares of iShares Russell 2000 Value ETF worth $15.1M as of Q1 2026.
  • Aspiriant LLC sold 2,532 iShares Russell 2000 Value ETF shares in Q1 2026, an estimated $490K.
  • iShares Russell 2000 Value ETF made up 0.43% of Aspiriant LLC's portfolio in Q1 2026, its #35 holding.
  • Aspiriant LLC first reported a position in iShares Russell 2000 Value ETF in Q2 2013 and has held it in 52 quarters since.
  • Aspiriant LLC's iShares Russell 2000 Value ETF position peaked at $21.8M in Q2 2021.
  • 1,028 funds tracked by Wall St. Rank held iShares Russell 2000 Value ETF as of Q1 2026.

Based on Aspiriant LLC's 13F filing for Q1 2026, filed 12 May 2026.